55134-13-9
Chemical Structure
Narasin
- CAS. Nr.: 55134-13-9
- Formula:C43H72O11
- Molecular Weight:765.03
IUPAC Name: (R)-2-((2R,3S,5S,6R)-6-((2S,3S,4S,6R)-6-((2S,5S,7R,9S,10S,12R,15R)-2-((2R,5R,6S)-5-ethyl-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)-15-hydroxy-2,10,12-trimethyl-1,6,8-trioxadispiro[4.1.57.35]pentadec-13-en-9-yl)-3-hydroxy-4-methyl-5-oxooctan-2-yl)-3,5-dimethyltetrahydro-2H-pyran-2-yl)butanoic acid
InChIKey: VHKXXVVRRDYCIK-CWCPJSEDSA-N
SMILES: O[C@H]1[C@@]2(O[C@](C)([C@]3([H])O[C@H]([C@](CC)(O)CC3)C)CC2)O[C@@]4(O[C@]([C@@H](C)C[C@H]4C)([H])[C@@H](CC)C([C@@H](C)[C@@H](O)[C@@H]([C@]5([H])O[C@@]([C@@H](C)C[C@@H]5C)([H])[C@@H](CC)C(O)=O)C)=O)C=C1
Biological Activity: Narasin is a cationic ionophore antibiotic and coccidiostat agent. Narasin inhibits NF-κB signaling and induces tumor cells apoptosis. Narasin has antimicrobial, antiviral anticancer activity. Narasin inhibits tumor metastasis and growth of ERα‑positive breast cancer cells by inactivation of the TGF-β/SMAD3 and IL‑6/STAT3 signaling pathways[1][2][3].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Narasin | 88.9% | Narasin is a cationic ionophore antibiotic and coccidiostat agent. Narasin inhibits NF-κB signaling and induces tumor cells apoptosis. Narasin has antimicrobial, antiviral anticancer activity. Narasin inhibits tumor metastasis and growth of ERα‑positive breast cancer cells by inactivation of the TGF-β/SMAD3 and IL‑6/STAT3 signaling pathways. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Ghada Bouguerra, et al. Stimulation of Eryptosis by Narasin. Cell Physiol Biochem. 2015;37(5):1807-16. [Content Brief]
- [2]. Low JS, et al. Narasin, a novel antiviral compound that blocks dengue virus protein expression. Antivir Ther. 2011;16(8):1203-18. [Content Brief]
- [3]. Chen J, et al. Narasin inhibits tumor metastasis and growth of ERα‑positive breast cancer cells by inactivation of the TGF‑β/SMAD3 and IL‑6/STAT3 signaling pathways. Mol Med Rep. 2020 Dec;22(6):5113-5124. [Content Brief]
